Abstract
Objective To explore the efficacy and safety of quetiapine and perphenazine in the treatment of Alzheimer's disease. Metbods 52 patients were randomly assigned to receive quetiapine of SO - 400mg daily ( 26 patients, study group), or perphenazine of 6-16mg daily ( 26 patients, control group )for 8 weeks. The efficacy and safety of the two therapies was compared between the two groups by using the Mini-mental State Examination ( MMSE ), Sandoz Clincal Assessment Geriatric ( SCAG ), and Treatment Emergent Symptom Scale (TESS ) 8 weeks after treatment. Results At the completion of treatment, the scores on MMSE were significantly higher ( P< 0.01 ), and those on SCAG were significantly lower in both groups ( P< 0.01 or P< 0.05 ), as compared with the baseline scores. The rate of adverse reactions was significantly lower in the study group than in the control group ( 30.8% vs. 46.2%, P< 0.05 ) Conclusions Quetiapine has a better efficacy in the treatment of Alzheimer's disease and has fewer adverse reactions. It is suitable for clinical use. Key words: Quetiapine; Senile dementia; Psychological and behavioral symptoms
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
